SEPTERNA
Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs).
SEPTERNA
Industry:
Biotechnology
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.septerna.com
Total Employee:
11+
Status:
Active
Contact:
650-338-3533
Total Funding:
100 M USD
Technology used in webpage:
Mimecast
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
Geneius
Geneius is a Biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Board_member
Investors List
Invus
Invus investment in Series A - Septerna
Catalio Capital Management
Catalio Capital Management investment in Series A - Septerna
Samsara BioCapital
Samsara BioCapital investment in Series A - Septerna
Logos Capital
Logos Capital investment in Series A - Septerna
BVF Partners
BVF Partners investment in Series A - Septerna
Third Rock Ventures
Third Rock Ventures investment in Series A - Septerna
Casdin Capital
Casdin Capital investment in Series A - Septerna
Official Site Inspections
http://www.septerna.com Semrush global rank: 4.25 M Semrush visits lastest month: 2.74 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Septerna"
About Us - Septerna
Septerna is a biotechnology company powered by our proprietary Native Complex Platform ... We have built a strong values-driven organization advancing cutting-edge science and relentlessly …See details»
Septerna
Feb 26, 2025 Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors. About Us ... values-driven …See details»
Septerna - Crunchbase Company Profile & Funding
Septerna is a biotechnology company that discovers and advances novel small-molecule medicines targeting G protein-coupled receptors. The company's …See details»
Careers - Septerna
We are a strong, values-driven organization advancing cutting-edge science and relentlessly focused on developing a portfolio of impactful new medicines for patients with significant unmet needs. View Open Positions. ... Info@septerna.com. Investors & Media Investors@septerna.com.See details»
Septerna, Inc. (SEPN) Company Profile & Facts - Yahoo Finance
See the company profile for Septerna, Inc. (SEPN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
Septerna 2025 Company Profile: Stock Performance & Earnings
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product ...See details»
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs ...
Feb 14, 2025 At Septerna, many of the 16 investors from the company’s Series A and B rounds had “very significant interest” in taking on larger positions, according to Finer. So as the IPO neared, Septerna needed to decide how it would balance …See details»
Septerna - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Septerna . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board Member and Advisor Profiles 4. Contacts 41. About. Septerna has 5 current employee profiles, including Chief Executive Officer and Co-Founder Jeffrey Finer. Septerna has 4 ...See details»
Septerna - Funding, Financials, Valuation & Investors - Crunchbase
Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases. New. Resources. Advanced Search. ... How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jul 11, 2023: Series B ...See details»
Septerna (SEPN) Company Profile & Description
Oct 25, 2024 Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, …See details»
Septerna - Company Profile - Tracxn
Jan 23, 2025 Septerna - Developer of GPCR drug discovery platform for multiple diseases. Public Company. Raised a total funding of $250M over 2 rounds from 16 investors. Founded by Jeff Finer and Ali Masoudi in the year 2020. Septerna has 810 competitors.See details»
Mission, Vision & Core Values of Septerna
Dec 19, 2024 At Septerna, our mission, vision, and core values serve as the guiding principles that shape every aspect of our organization. With a commitment to excellence, innovation, and unity, we strive to elevate our industry and exceed the expectations of our clients. Our vision is to lead by example, inspire change, and make a lasting impact on the world.See details»
Septerna Expands Leadership with Appointment of Industry …
Jan 6, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma …See details»
Investor FAQs - Septerna
Oct 24, 2024 Septerna is headquartered at 250 East Grand Avenue, South San Francisco, CA 94080. The main phone number is (650) 338-3533. Press space to expand and collapse this section. When was the company founded? Septerna was founded and commenced operations in December 2019 under the name GPCR NewCo, Inc. In June 2021, the company changed its …See details»
Press Releases - Septerna
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering ofSee details»
Septerna Expands Leadership with Appointment of Industry …
Jan 6, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug ...See details»
Septerna appoints new CFO to bolster financial strategy
Jan 6, 2025 All three firms highlighted Septerna's strong financial position, with a cash runway extending into the second half of 2027, expected to support ongoing research and development efforts.See details»
ir.septerna.com
Feb 18, 2025 Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates ...See details»
Septerna Inc, SEPN:NMQ profile - FT.com - Financial Times
Mar 7, 2025 Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation ...See details»
Septerna sinks as it discontinues lead asset SEP-786
Feb 19, 2025 US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.See details»